-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The biopharmaceutical industry is an emerging strategic industry in China.
With the intensification of aging, the continuous upgrading of consumption, and the advancement of a series of favorable policies, the scale of the domestic biopharmaceutical industry market continues to expand
.
The industry predicts that in the next ten years, China's biomedical industry market will usher in a spurt of development
.
Data shows that the scale of China's biomedical industry will reach 3.
57 trillion yuan in 2020, and it is expected to exceed 4 trillion yuan by 2022 and 5 trillion yuan in 2025, with an average annual growth rate of about 8%
.
It is worth mentioning that the biomedical industry is a technology-intensive industry, and innovative elements such as information, talents, and technology are important driving forces for industrial development
.
Under the background of shortage of talents, insufficient funds, and low speed of transformation of research results, Shanghai's Songjiang District biomedical companies have shown a prosperous development through the G60 Science and Technology Innovation Corridor
.
Songjiang is the main battlefield of Shanghai's advanced manufacturing industry and attaches great importance to new opportunities for the development of the biomedical industry
.
As early as the construction of the G60 Science and Technology Corridor in the Yangtze River Delta, Songjiang included biomedicine in the key sectors of the industrial map
.
In recent years, Shanghai Songjiang has successively introduced a number of companies covering chemical drugs, biological drugs, medical devices and other subdivisions such as G60 Brain Intelligence Science and Technology Innovation Base, Fuhong Henlius, Huadao Biology, etc.
, to create research and development, clinical trials, and production.
Biomedicine innovation source and biomedical industry cluster of the whole industry chain such as processing
.
As of June this year, there are nearly 3,000 companies related to the biomedical industry in Songjiang District, of which more than 1,800 were registered after the start of the construction of the Yangtze River Delta G60 Science and Technology Innovation Corridor in 2016, achieving a five-year increase of 1.
5 times and surpassing the acceleration of high-quality development.
.
In the first half of 2021, the total output value was 6.
35 billion yuan, a year-on-year increase of 18%
.
In addition, since 2016, a total of 24 key biomedical industry projects have landed in Songjiang, with a planned total investment of 20 billion yuan, and an estimated annual output value of about 23 billion yuan after reaching production
.
Behind the rapid development of Shanghai Songjiang's biomedical industry, a series of favorable policies have also continued to be introduced
.
In recent years, Songjiang District has formulated industrial policies such as "Several Policies and Regulations on Accelerating the Development of High-Quality Clusters of Biomedical Industry in Songjiang District" and "Several Measures to Promote the Development of High-Quality Clusters of Medical Device Industry in the District" to promote the development of biomedical companies.
Fast lane"
.
Among them, a number of policies and regulations provide special support for the development of Songjiang's biomedical industry from the three aspects of industrial high-quality agglomeration development, industrial independent innovation and transformation, and creation of a good industrial development environment, which also strengthened the development of biomedical companies in Songjiang.
Confidence
.
Several measures have reduced the time limit for the medical device business license to be completed from the original 20 working days to 5 working days, creating a "fast lane" for the precise investment promotion of the medical device industry, and better serving the enterprises to handle and operate in Songshan
.
Up to now, the number of applications for Songjiang Class III medical device business licenses has increased by 246.
9% compared with 2016
.
It is understood that during the "14th Five-Year Plan" period, Songjiang is in the critical stage of accelerating the construction and improvement of the advanced manufacturing industry ecosystem, and will build several 100-billion-level and tens-billion-level industrial clusters, including biomedical industry clusters.
.
In the future, Songjiang will gather talents, capital, technology and other development factors to enhance the independent controllability of the supply chain of the industrial chain.
With biotechnology drugs and modern medical equipment manufacturing as the core and leading areas, Songjiang will strive to create a "biomedical manufacturing aircraft carrier-type agglomeration area" And "Medical Device Manufacturing Innovation Demonstration Base"
.
With the intensification of aging, the continuous upgrading of consumption, and the advancement of a series of favorable policies, the scale of the domestic biopharmaceutical industry market continues to expand
.
The industry predicts that in the next ten years, China's biomedical industry market will usher in a spurt of development
.
Data shows that the scale of China's biomedical industry will reach 3.
57 trillion yuan in 2020, and it is expected to exceed 4 trillion yuan by 2022 and 5 trillion yuan in 2025, with an average annual growth rate of about 8%
.
It is worth mentioning that the biomedical industry is a technology-intensive industry, and innovative elements such as information, talents, and technology are important driving forces for industrial development
.
Under the background of shortage of talents, insufficient funds, and low speed of transformation of research results, Shanghai's Songjiang District biomedical companies have shown a prosperous development through the G60 Science and Technology Innovation Corridor
.
Songjiang is the main battlefield of Shanghai's advanced manufacturing industry and attaches great importance to new opportunities for the development of the biomedical industry
.
As early as the construction of the G60 Science and Technology Corridor in the Yangtze River Delta, Songjiang included biomedicine in the key sectors of the industrial map
.
In recent years, Shanghai Songjiang has successively introduced a number of companies covering chemical drugs, biological drugs, medical devices and other subdivisions such as G60 Brain Intelligence Science and Technology Innovation Base, Fuhong Henlius, Huadao Biology, etc.
, to create research and development, clinical trials, and production.
Biomedicine innovation source and biomedical industry cluster of the whole industry chain such as processing
.
As of June this year, there are nearly 3,000 companies related to the biomedical industry in Songjiang District, of which more than 1,800 were registered after the start of the construction of the Yangtze River Delta G60 Science and Technology Innovation Corridor in 2016, achieving a five-year increase of 1.
5 times and surpassing the acceleration of high-quality development.
.
In the first half of 2021, the total output value was 6.
35 billion yuan, a year-on-year increase of 18%
.
In addition, since 2016, a total of 24 key biomedical industry projects have landed in Songjiang, with a planned total investment of 20 billion yuan, and an estimated annual output value of about 23 billion yuan after reaching production
.
Behind the rapid development of Shanghai Songjiang's biomedical industry, a series of favorable policies have also continued to be introduced
.
In recent years, Songjiang District has formulated industrial policies such as "Several Policies and Regulations on Accelerating the Development of High-Quality Clusters of Biomedical Industry in Songjiang District" and "Several Measures to Promote the Development of High-Quality Clusters of Medical Device Industry in the District" to promote the development of biomedical companies.
Fast lane"
.
Among them, a number of policies and regulations provide special support for the development of Songjiang's biomedical industry from the three aspects of industrial high-quality agglomeration development, industrial independent innovation and transformation, and creation of a good industrial development environment, which also strengthened the development of biomedical companies in Songjiang.
Confidence
.
Several measures have reduced the time limit for the medical device business license to be completed from the original 20 working days to 5 working days, creating a "fast lane" for the precise investment promotion of the medical device industry, and better serving the enterprises to handle and operate in Songshan
.
Up to now, the number of applications for Songjiang Class III medical device business licenses has increased by 246.
9% compared with 2016
.
It is understood that during the "14th Five-Year Plan" period, Songjiang is in the critical stage of accelerating the construction and improvement of the advanced manufacturing industry ecosystem, and will build several 100-billion-level and tens-billion-level industrial clusters, including biomedical industry clusters.
.
In the future, Songjiang will gather talents, capital, technology and other development factors to enhance the independent controllability of the supply chain of the industrial chain.
With biotechnology drugs and modern medical equipment manufacturing as the core and leading areas, Songjiang will strive to create a "biomedical manufacturing aircraft carrier-type agglomeration area" And "Medical Device Manufacturing Innovation Demonstration Base"
.
